Search

Home > New FDA Approvals > 109 - Hizentra for chronic inflammatory demyelinating polyneuropathy; hydroxyurea tablets for pediatric sickle cell anemia; OV101 for Fragile X Syndrome; somatropin for short stature, Prader-Willi syndrome in children.
Podcast: New FDA Approvals
Episode:

109 - Hizentra for chronic inflammatory demyelinating polyneuropathy; hydroxyurea tablets for pediatric sickle cell anemia; OV101 for Fragile X Syndrome; somatropin for short stature, Prader-Willi syndrome in children.
Category: Science & Medicine
Duration: 00:08:04
Publish Date: 2018-03-19 07:00:00
Description:

March 19, 2018

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

1:16 Hizentra approved for chronic inflammatory demyelinating polyneuropathy https://www.empr.com/news/hizentra-immune-globulin-chronic-inflammatory-demyelinating-polyneuropathy/article/751557/

3:11 FDA approves hydroxyurea tablets for pediatric patients with sickle cell anemia http://www.mdmag.com/medical-news/fda-approves-hydroxyurea-tablets-for-pediatric-patients-with-sickle-cell-anemia

4:33 OV101 granted fast track designation for treatment of Fragile X Syndrome https://www.streetinsider.com/dr/news.php?id=13947160&gfv=1

6:22 FDA approves somatropin for short stature, Prader-Willi syndrome in children https://www.healio.com/endocrinology/hormone-therapy/news/online/%7Bdcc3b5aa-ef25-4e8e-a19c-4b358b336ee4%7D/fda-approves-somatropin-for-short-stature-prader-willi-syndrome-in-children 

Brought to you by Nascent Medical. For assistance with medical writing, please email info@nascentmc.com.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0